Etienne de Villers-Sidani
Chief Executive Officer at 10032506 Canada, Inc.
Etienne de Villers-Sidani active positions
| Companies | Position | Start | End |
|---|---|---|---|
10032506 Canada, Inc.
 10032506 Canada, Inc. Packaged SoftwareTechnology Services 10032506 Canada, Inc. is a Canadian Montreal-based company founded in 2016 by Marc Reeves, Etienne de Villers-Sidani, and Yves Desgagné. The company has developed a patented mobile technology for capturing digital biomarkers of neurodegenerative and mental diseases such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, and related disorders, frontotemporal dementia, and related disorders, as well as cancer-related cognitive disorders ("chemo brain"). The technology is embodied in an ISO/HIPAA-compliant system consisting of an intuitive iPad Pro application connected to a cloud-based artificial intelligence infrastructure. The application consists of a series of simple visual tasks that are completed in a matter of minutes, and the users' eye movements and gaze patterns are extracted and recorded in the form of hundreds of measurements called eye movement biomarkers (EMB) and gaze mapping biomarkers (GMB). The company's mission is to become the digital leader in mobile applications that can easily extract EMBs and GMBs through its AI-powered technology to better meet the needs of the healthcare system. Etienne de Villers-Sidani has been the CEO since 2016. | Chief Executive Officer | 31/12/2015 | - |
| Founder | 31/12/2015 | - |
Career history of Etienne de Villers-Sidani
Statistics
International
| Canada | 2 |
Operational
| Chief Executive Officer | 1 |
| Founder | 1 |
Sectoral
| Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
10032506 Canada, Inc.
10032506 Canada, Inc. Packaged SoftwareTechnology Services 10032506 Canada, Inc. is a Canadian Montreal-based company founded in 2016 by Marc Reeves, Etienne de Villers-Sidani, and Yves Desgagné. The company has developed a patented mobile technology for capturing digital biomarkers of neurodegenerative and mental diseases such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, and related disorders, frontotemporal dementia, and related disorders, as well as cancer-related cognitive disorders ("chemo brain"). The technology is embodied in an ISO/HIPAA-compliant system consisting of an intuitive iPad Pro application connected to a cloud-based artificial intelligence infrastructure. The application consists of a series of simple visual tasks that are completed in a matter of minutes, and the users' eye movements and gaze patterns are extracted and recorded in the form of hundreds of measurements called eye movement biomarkers (EMB) and gaze mapping biomarkers (GMB). The company's mission is to become the digital leader in mobile applications that can easily extract EMBs and GMBs through its AI-powered technology to better meet the needs of the healthcare system. Etienne de Villers-Sidani has been the CEO since 2016. | Technology Services |
